Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695521 · ClinicalTrials.gov registry record · Phase 1
Regulatory T Cells for Amyotrophic Lateral Sclerosis
A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Cellenkos.
- Active
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT05695521 is a Phase 1 study of Amyotrophic Lateral Sclerosis that is active but no longer recruiting, run by Cellenkos. The registered enrollment target is 66 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05695521, a Phase 1 study of Amyotrophic Lateral Sclerosis, is active but no longer recruiting, sponsored by Cellenkos.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.
Conditions Studied
Interventions
- BIOLOGICAL CK0803
- OTHER Excipient
Study Locations (3)
Texas
- Baylor College of Medicine - Houston
- Michael E. DeBakey Veterans Affairs Medical Center - Houston
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05695521
The ClinicalTrials.gov registry entry for NCT05695521 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (93% lower). The listed sponsor is Cellenkos, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which CK0803 is the first listed.
NCT05695521 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, New York.
Frequently Asked Questions
What is clinical trial NCT05695521 about?
NCT05695521 is a clinical study titled "Regulatory T Cells for Amyotrophic Lateral Sclerosis". Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.
What is the current status of trial NCT05695521?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-04-03. Estimated completion is 2027-12.
What conditions does trial NCT05695521 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT05695521?
The interventions under investigation include: CK0803 (BIOLOGICAL), Excipient (OTHER).
Who is sponsoring clinical trial NCT05695521?
This trial is sponsored by Cellenkos, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05695521 being conducted?
This trial has 3 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
RECRUITING · Phase 1
-
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RECRUITING · Phase 1
-
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.